| GPRO 1.5587 77.89% | LIDR 1.485 29.13% | RITR 0.092899 0.98% | FLYE 1.9501 43.39% | RZLV 2.325 -19.55% | HKPD 0.3533 6.00% | NIO 4.115 -2.72% | BIAF 6.6978 46.88% | AIM 0.2474 9.47% | NVDA 217.5972 -1.44% | TSLL 9.46 -5.12% | SOXL 102.8 -8.86% | NVD 4.0499 3.05% | NCPL 0.7943 11.00% | TQQQ 69.4786 -3.39% | INTC 86.4988 -3.36% | SOXS 53.44 9.02% | SSM 3.99 48.88% | SPCX 143.81 0.08% | GYGY 1.39 16.81% | PCG 13.245 -0.19% | IBIT 44.315 -0.79% | AUUD 0.9947 0.76% | SQQQ 39.81 3.38% | AMBR 1.0699 -7.77% | FRVO 18.975 23.37% | AAPL 325.3629 2.69% | ZEO 0.2132 -10.31% | NOK 9.775 -3.60% | BITO 10.535 -0.89% | SGOV 100.4 -0.29% | ONDS 7.185 -6.15% | TSLA 358.63 -2.53% | PFE 28.805 1.21% | PLUG 2.125 -1.62% | VVOS 0.1718 -12.35% | OPEN 3.1212 -2.46% | SOFI 17.525 -1.99% | WETO 6.205 13.23% | BMNR 24.16 -4.58% | IREN 35.5885 -4.11% | TLT 82.2886 -0.28% | BTG 5.345 -2.46% | NU 14.845 2.03% | HOOD 105.3 0.47% | XLE 64.25 0.45% | AMZN 254.59 -1.99% | GDX 97.7 -0.82% | HYG 79.295 -0.65% | FNGR 0.2157 -3.27%

Nutex Health Inc. (NASDAQ:NUTX) Surpasses Earnings Expectations

Nutex Health Inc. (NASDAQ:NUTX) is a physician-led, integrated healthcare delivery system. It operates 24 micro hospitals and hospital outpatient departments across 11 states, along with primary care-centric, risk-bearing physician networks. The company focuses on providing efficient healthcare services, which is reflected in its recent financial performance.

On November 19, 2025, Nutex Health reported earnings that exceeded expectations. The company achieved a revenue of approximately $244 million, surpassing the estimated $222 million. This success is part of a broader financial upturn for the first half of 2025, where total revenue reached $455.8 million, a 217.5% increase from the same period in 2024.

Nutex Health's net income for the first half of 2025 was $3.5 million, a significant improvement from a net loss of $0.7 million in 2024. This $4.2 million increase highlights the company's turnaround. The diluted income per share rose to $0.55, contrasting with a loss per share of $0.15 the previous year, indicating improved profitability for shareholders.

The company's EBITDA for the first half of 2025 was $51.1 million, up from $15.6 million in 2024, representing a 227.4% increase. Adjusted EBITDA saw an even more dramatic rise, reaching $144.4 million, a 2144.2% increase from $6.4 million in 2024. This growth underscores Nutex Health's operational efficiency and financial health.

Nutex Health's financial metrics reflect its market position. With a P/E ratio of approximately 10.43 and a price-to-sales ratio of about 0.70, the company is valued attractively compared to its earnings and sales. The enterprise value to sales ratio is roughly 0.97, and the enterprise value to operating cash flow ratio is approximately 5.84, indicating efficient cash flow management. The debt-to-equity ratio of approximately 0.94 and a current ratio of around 2.43 demonstrate a balanced approach to debt and strong liquidity.

Published on: November 19, 2025